PHARMACOLOGIE EXPÉRIMENTALE

Roncalli J, Smih F, Desmoulin F, Dumonteil N, Harmancey R, Henning S, Perez L, Pathak A, Galinier M, Massabuau P, Malet-Martino M, Sénard JM, Rouet P. NMR and cDNA array analysis prior to heart failure reveals an increase of unsatured lipids, a glutamine/glutamate ration decrease and a specific tenascriptome adaptation in obese rat heart. J Mol Cell Cardiol 2007 ; 42(3) : 526-539

Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzki J. Evidence for phosphodiesterase-5A and neutral endopeptidase activities in human adipocyte : role in atrial natriuretic peptide-mediated lipolysis. British J Pharmacol 2007 (in press).

Moro C, Pillard F, De Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in man. Am J Physiol Regul Integr Comp Physiol 2007. 293 : R612-R617.

Crassous PA, Denis C, Paris H, Sénard JM. Interest of a2-adrenergic agonists and antagonists in clinical practice : background, facts and perspectives. Curr Topics Médicament Chem 2007 ; 7 (2) : 187-194

Arellano C, Philibert C, Vachoux C, Woodley J, Houin G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption : in vitro studies with rat everted Gut sac…J Pharm Pharmaceut Sci 2007, 10, 1, 26-36.

Harmancey R, Sénard JM, Rouet P, Pathak A, Smih F. Adrenomedullin and PAMP inhibit adipogenesis under the transcriptional control of insulin. Diabetes 2007 Mars ; 56(3) : 553-563.

Moro C, Pillard F, De Glisezinski I, Klimcakova E, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Subcutaneous adipose tissue lipolysis is mainly due to atrial natriuretic peptide in overweight men during exercise. International Journal of Obesity ; 31, suppl 1, may 2007.

Pillard F, Moro C, Harant I, Garrigue E, Lafontan M, Berlan M, Crampes F, De Glisenzinski I, Rivière D. Lipid oxidation according to intensity and exercise duration in overweight men and women. International Journal of Obesity ; 15, 2256-2262.

Polak J, Moro C, Bessière D, Hejnova J, Marquès MA, Bajzova M, Crampes F, Lafontan M, Berlan M, Stich V. Acute exposure to long-chain fatty acid impairs alpha2-adrenergic mediated antilipolysis in human adipose tissue. J Lip Res 2007, 48, 2236-2246.

PHARMACOLOGIE CLINIQUE

Goetz CG, Damier Ph, Hicking C, Laska E, Müller Th, Olanow CW, Rascol O, H Russ. Sarizotan as a treatment for dyskinesias in Parkinson’s disease : A double-blind placebo-controlled trial. Movement Disorders 2007 ; 22 : 179-186.

Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, Brefel-Courbon C. Levodopa raises objective painthresold in Parkinson’s disease : a RIII reflex study. J Neurol Neurosurg Psychiatry 2007, 78 : 1140-1142.

Goetz CC, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holoway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society - Sponsored Revision of the Unified Parkinson’s Disease Rating Scale : (MDS-UPDRS) : process, format and clinimetric testing plan. Movement Disorders 2007 ; 22 : 41-47.

Schrag A, Barone P, Brown RG, Leentjens AFG, McDonald WM, Starkstein S, Weintraud D, Poewe W, Rascol O, Sampaio C, Stebbing GT, Goetz CG. Depression rating scales in Parkinson’s disease : critique and recommendations. Movement Disorders 2007 ; 22 : 1077-1092.

Damier Ph, Thobois S, Witjas T, Cuny E, Derost Ph, Raoul S, Mertens P, Perragut JC, Lemaire JJ, Burbaud P, Rascol O and the French STARDYS group. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psych 2007 ; 64 : 170-176.

Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M, Fabre N, Lotterie JA, Chaynes P, Berry I, Lazorthes Y, Rascol O. Does ageing influence deep brain stimulation outcomes in Parkinson’s disease. Movement Disorders 2007 ; 22 : 1457-1463.

Ferreira J, Silva JM, Freire R, Pignatelli J, Correia Guesdes L, Feijo A, Rosa MM, Coelho M, Costa J, Noronha A, Hewett R, Marques Gomes A, Cirne de Castro JL, Rascol O, Sampaio C. Skin cancers and precancerous lesions in Parkinson’s disease patients. Movement Disorders 2007 ; 22 : 1471-1475.

Seppi K, Rascol O. Dementia with lewy body and Parkinson’s disease with dementia : can MRI make the difference ? Neurology 2007, 69 : 717-718.

Pathak A, Hanon O, Negre-Pages L, Sevenier F, on behalf of the OSCAR investigators. Rationale, design and methods of the OSCAR study : observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. Fundam Clinic Pharmacol 2007, 21 : 199-205.

Jouret B, Ahluwalia N, Cristini C, Dupuy M, Nègre-Pages L, Grandjean H, Tauber M. Factors associated with overweight in preschool-age children in southwestern France. Am J Clin Nutr 2007, 85 : 1643-9.

Polak J, Moro C, Bessière D, Hejnova J, Marquès MA, Bajzova M, Crampes F, Lafonton M, Berlan M, Stich V. Short-term exposition to saturated fatty acids inhibits adrenergic alpha-2 antilipolytic effect in human adipose tissue. International Journal of Obesity ; 31, suppl 1, may 2007.

Moro C, De Glisezinski I, Crampes F, Pillard F, Thalamas C, Harant I, Marquès MA, Lafontan M, Berlan M. Atrial natriuretic peptide increases lipid mobilization and utilization during head-down bed rest in man. Fundam Clin Pharmacol 2007, 21, suppl 1, 98.

Polak J, MoroC, Kimcakova E, Kovacikova M, Barjova M, Vitkova M, Kovacova Z, Sotornik R, Berlan M, Viguerie N, Langin D, Stich V. The atrial natriuretic peptide and catecholamine-induced lipolysis and expression of related genes in adipose tissue in hypothyroid and hyperthyroid patients. Am J Physiol 2007, 293 : R612-R617.

Pillard F, Moro C, Harant I, Garrigue E, Guilland JC, Thalamas C, Lafontan M, Berlan M, Crampes F, De Glisezinski I. Lipid mobilization : a limiting factor of lipid oxidation in trained men. Fundam Clin Pharmacol 2007, 21, suppl 1, 99.

Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, Bouloumie A, Galitzki J, Arner P, Langin D. Atrial natriuretic peptide inhibits the production of adipokines and cytokines liked to inflammation in human subcutaneous adipose tissue. Diabetologia 2007, 50 : 1038-1047.

Moro C, Pillard F, De Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Sex differences in lipolysis-regulating mechanisms in overweight srjects : effect of exercise intensity. International Journal of Obesity 2007 ; 15, 2245-2255.

Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn N, Mathias Ch, Tolosa E, Cardozo A, Dizdar N, Rascol O, Slaoui T, Growth-Hormone MSA Study Group, European MSA Study Group (EMSA-SG). Safety and tolerability of growth hormone therapy in multiple system atrophy : a double-blind, placebo-controlled study. Movement Disorders 2007 ; 22 : 1138-144.

Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, on behalf on the SP515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease : a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 ; 6 : 513-520.

Fuzier V, Fuzier R, Conan L, Montastruc JL. Nalador® (sulprostone) : précautions d’emploi et utilisation pratiqur dans l’hémorragie du post-partum. LPAR 2007, 379-385.

Pathak A, Sommet A, Montastruc JL. Interactions médicamenteuses chez le cardiaque très âgé. Arch Mal Cœur & Vaisseaux 2007, 158 : 13-21.

Conil JM, Georges B, Lavit M, Seguin T, Tack I, Samii K, Chabanon G, Houin G, Saivin S. Pharmacokinetics of ceftazidime and cefepime in burn patients : the importance of age and creatinine clearance. Int J Clin Pharmacol Toxicol 2007, 45, 10, 529-538.

Barone P, Goetz CG, Houben JJ, Koester J, Leentjens AF, Poewe W, Rascol O, Reichmann H, Schapira AH, Tolosa E. PRODESTstudy – Depressive symptoms in Parkinson’s disease : demographic data. Movement Disorders 2007, suppl 16, S183, 593.

Brefel-Courbon C, Payoux P, Ory F, Thalamas C, Rascol O. Nociceptive brain activation in painful patients with Parkinson’s disease. Movement Disorders 2007, suppl 16, S150, 489.

Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G, Saivin S. A population pharmakcokinetic approach toceftazidime use in burns patients : influence of glomerular filtration, gender and mechanical ventilation. Brit J Clin Pharmacol. 2007

Conil M, Georges B, Fourcade O, Seguin T, Houin G, Saivin S. Intermittent administration of ceftazidime to burns patients : influence of glomerular filtration. Int J Clin Pharmacol Toxicol 2007, 45, 10, 259-538.

Gandia Mailly P, Idier I, Houin G. Is once mesalazine equivalent to the currently used twice-daily regimen ?a study performed in 30 healthy volunteers. J Clin Pharmacol 2007, 47, 334-342.

Gandia P, Bour D, Maurette JM, Donazzolo Y, Duchene P, Bejot M, Houin G. A biovailability stuydy comparing two oral formulations containing zinc (zn bisglycinate vs zn gluconate) after a single administration to twelve healthy female volunteers. Int J Vit Nut Res 2007, 4, 243-248.

Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AHV, on behalf of the SP513 investigators. Rotigotine transdermal patch in early Parkinson’s disease : a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22 : 2398-2404.

Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Olanow CW, Rascol O, Russ H. Placebo influences on dyskinesia in Parkinson’s disease. Movement Disorders 2007, suppl 16, S243, 794.

Goetz CG, Tilley BC, Shaftman S, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees AJ, Leurgans S, Le Witt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi J, Van Hilten JJ. Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version. Movement Disorders 2007, suppl 16, S6, 18.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Boeuf O, Lapeyre-Mestre M, on behalf of the French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse en France - Results of OSIAP survey. Drug Safety 2007, 30 : 265-276.

Lacroix I, Hurault C, Saivin S, Raoul V, Berrebi A, Souchet E, Desboeuf K, Montastruc JL, Damase-Michel C. Exposition in utero à des substances psychoactives : résultats de l’étude "NENUPHAR". Thérapie 2007, 62 : 177-183.

Sommet A, Bagheri H, Damase-Michel C, Pathak A, Montastruc JL. Tamiflu® et grippe aviaire. Pratiques 2007, 36 : 78-82.

Sommet A, Bagheri H, Montastruc JL. De la Pharmacovigilance à la gestion des risques. La Lettre du Pharmacologue 2007, 21 : 26-31.

Montastruc JL. Médicaments "antidiabétiques", médicaments "hypoglycémiants" : ne pas confondre !. Rev Prescrire 2007, 27 ; 288 : 793.

Montastruc P. La gymnastique est-elle née "produit de santé" ?. Rev Prescrire 2007, 27 ; 282 : 312-313.

Tavassoli N, Gardette V, Sommet A, Lapeyre-Mestre M, Bagheri H, Andrieu S, Vellas B, Montastruc JL. Interactions médicamenteuses des anticholinestérasiques : à propos de 1058 notifications spontanées dans la Banque Nationale Française de Pharmacovigilance. Rev Neurol 2007, 163 : 76-77.

Montastruc JL – Effets indésirablescardiovasculaires des AINS classiques : attention ! . Rev ADPHSO, 2007, 32,1, 58.

Montastruc JL –Attention aux extrapolations physiopathologiques hâtives à propos des médicaments. Rev ADPHSO, 2007, 32,1, 66.

Montastruc JL – Les endoprothèses pharmaco actives sont-elles dangereuses ? Rev ADPHSO, 2007, 32,1, 66.

Montastruc JL – Mort subite du sportif : imputabilité des androgènes ? Rev ADPHSO, 2007, 32,1, 66.

Montastruc JL – Bosentan. Rev ADPHSO, 2007, 32,1, 65.

Montastruc JL – Quatre décès sur cinq chez l’asthmatique pourraient être dus aux agonistes béta2 acrénergiques à longue durée d’action !. Rev ADPHSO, 2007, 32,1, 65.

Montastruc JL – Prométhazine et dépression respiratoire chez l’enfant. Rev ADPHSO, 2007, 32,1, 64.

Montastruc JL – Exposition in utéro au DES DISTILBENE® et troubles psychiatriques : des données rassurantes. Rev ADPHSO, 2007, 32,1, 64.

Montastruc JL – Arrêter les alpha-bloquants avant une opération de la cataracte. Rev ADPHSO, 2007, 32,1, 63.

Montastruc JL – Insuffisances rénales aigues sous immunoglobulines humaines polyvalentes I.V. Rev ADPHSO, 2007, 32,1, 62.

Montastruc JL – Campagne anti-tabac ou campagne publicitaire pour les médicaments ?. Rev ADPHSO, 2007, 32,1, 62.

Montastruc JL – Connaître les effets indésirables des glitazones. Rev ADPHSO, 2007, 32,1, 61.

Montastruc JL – Biphosphonates et douleurs osseuses. Rev ADPHSO, 2007, 32,1, 59.

Montastruc JL – Ostéonécrose de la mâchoire et biphosphonates : le point . Rev ADPHSO, 2007, 32,1.

Montastruc JL – Risque infectieux et anti-TNF Alpha . Rev ADPHSO, 2007, 32,1, 58.